Business Wire

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall

21.5.2026 15:00:00 EEST | Business Wire | Press release

Share

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/

The Live Moment Effect report from Genius Sports and MediaScience.

The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions.

The Moment Before the Ad Matters

The research challenges long-held assumptions about media value, showing that not all impressions are equal.

Live sports remain one of the last entertainment formats with large-scale audiences. According to Sports Business Journal, sports accounted for 96 of the top 100 most-watched U.S. telecasts of 2025. But scale alone does not make every impression equally valuable. Fans’ attention rises and falls with the action, making the moments immediately after high-intensity plays especially powerful for advertisers. Cutting through requires knowing when those moments occur and being ready to reach the right fans in real time with messaging tailored to the moment.

Key findings include:

  • Emotional intensity immediately before an ad significantly increases memory encoding and recall
  • The 60 seconds following a high-impact moment represent the peak window for advertising effectiveness
  • Emotional context can have a greater influence on recall than the ad creative itself in real time.

A Shift from Buying Media to Activating Moments

The findings point to a fundamental shift in how sports media should be planned and valued. The Live Moment Effect research shows that recall is concentrated around moments of peak emotion. As a result, aligning ad delivery and ad messaging with real-time game context can significantly improve campaign outcomes.

Genius Sports is applying these insights through the Genius Sports Moment Engine, which uses official game data and real-time signals to identify and activate around high-impact moments as they occur. By enabling brands to align campaigns with peak attention windows, the Genius Sports Moment Engine allows advertisers to improve outcomes by optimizing timing rather than increasing volume.

“The sports advertising playbook is being rewritten around the moments when fans are most emotionally engaged,” said Josh Linforth, Chief Revenue Officer at Genius Sports. “Brands should be present across the full fan journey — pre-game, in-game and post-game — because every stage of the sports experience creates an opportunity to connect. Within that always-on presence, this research shows that certain moments carry extra impact. When a momentum shift, near score or decisive play changes how fans are feeling and focusing, the message should change with it. Genius Sports Moment Engine uses official game data and real-time signals to help advertisers identify those high-impact windows as they happen and tailor campaigns accordingly across every screen.”

“Our research continues to reinforce a principle we’ve observed across the media landscape: context matters,” said Phillip Lomax, Chief Revenue Officer at MediaScience. “In live sports, emotionally heightened moments prime audiences differently, changing their cognitive and emotional state before an ad is even delivered. When an advertisement aligns with that moment, the context and the creative converge to strengthen memory encoding and significantly amplify recall. That creates a meaningful opportunity for brands to improve performance through real-time, moment-based activation rather than simply increasing media volume.”

The research analyzed viewer response to advertising across varying levels of emotional intensity during live sports, measuring attention, cognitive engagement, and brand recall in controlled environments. Access the full study here.

About Genius Sports

Genius Sports is the official data, technology and broadcast partner that powers the global sports, betting and media ecosystem. As the operating system of modern sport, our technology is used in over 150 countries worldwide, creating highly immersive products that enrich fan experiences across the entire sports industry.

We are the trusted partner to over 1,000 sports organizations, including many of the world’s largest leagues, teams, sportsbooks, brands and broadcasters, such as the NFL, English Premier League, NCAA, DraftKings, FanDuel, bet365, Coca-Cola, EA Sports, CBS, NBC and ESPN.

Genius Sports is uniquely positioned through AI, computer vision and big data to power the future of sports fan experiences. From delivering augmented broadcasts and enhanced highlights, to automated officiating tools, immersive betting solutions and personalized marketing activations, we connect the entire sports value chain from the rights holder all the way through to the fan.

About MediaScience

MediaScience is the industry leader in media and advertising innovation research, trusted by major networks and platforms including Disney, NBCUniversal, Google and most other national TV networks and social media platforms. The company's work at the intersection of science and creativity continues to redefine how stories are told, measured, and experienced in the modern media landscape.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260521475265/en/

Contacts

Tony Marlow
CMO, Genius Sports
tony.marlow@geniussports.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

Cranium AI and ISTARI Forge Global Alliance to Drive Enterprise AI Security and Governance21.5.2026 13:00:00 EEST | Press release

Cranium AI, the leading end-to-end AI Security and Governance platform, and ISTARI, a leading cyber resilience advisory firm, today announced a strategic partnership to provide global organizations with an end-to-end AI security & governance solution. As organizations accelerate AI adoption, they face a critical challenge: implementing actionable, operational AI governance while keeping pace with the speed of the AI landscape. This collaboration bridges that gap by merging Cranium’s cutting-edge AI security and governance platform with ISTARI’s deep advisory expertise in cyber risk and operating model design. Together, the firms provide a powerful, end-to-end solution for enterprises navigating the complexities of AI transformation. A Unified Vision for Sustainable AI Governance The partnership is built on a shared mission to move organizations beyond fragmented AI initiatives toward fully operationalized, secure, and governed programs. By combining Cranium’s platform automation with I

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye